NfL has recently been investigated in cancer patients receiving neurotoxic agents, and previous research evidence demonstrates that NfL levels increase in close relation to the severity of CIPN during chemotherapy and decline after its cessation [4, 5, 6, 7, 8, 9, 10] (Table S1), clearly highlighting the potential role of blood NfL as a biomarker of CIPN evolution through time. Here, NEFL is linked to cancer.